Repligen Corporation (NASDAQ:RGEN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Repligen Corporation (NASDAQ:RGEN) have been given an average recommendation of “Moderate Buy” by the eighteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, thirteen have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $165.00.

A number of research analysts recently weighed in on the stock. Wolfe Research assumed coverage on shares of Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price on the stock. Roth Capital initiated coverage on Repligen in a research note on Friday, April 17th. They issued a “buy” rating and a $160.00 price target for the company. Royal Bank Of Canada initiated coverage on Repligen in a report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price target on the stock. Canaccord Genuity Group lowered their price objective on Repligen from $165.00 to $145.00 and set a “hold” rating on the stock in a research report on Monday, April 20th. Finally, Rothschild & Co Redburn set a $160.00 price objective on Repligen and gave the stock a “buy” rating in a research note on Friday, April 17th.

Repligen Trading Up 0.6%

Repligen stock opened at $148.06 on Thursday. Repligen has a 12-month low of $100.99 and a 12-month high of $175.77. The firm has a market capitalization of $8.35 billion, a price-to-earnings ratio of 164.51, a P/E/G ratio of 2.83 and a beta of 1.06. The firm has a 50 day moving average of $127.77 and a 200 day moving average of $133.55. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. The business had revenue of $194.25 million for the quarter, compared to the consensus estimate of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, research analysts predict that Repligen will post 1.99 earnings per share for the current year.

Insider Transactions at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. The trade was a 3.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On Repligen

A number of institutional investors have recently added to or reduced their stakes in the stock. Wasatch Advisors LP raised its position in shares of Repligen by 27.9% during the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock valued at $216,974,000 after buying an additional 346,720 shares during the last quarter. Handelsbanken Fonder AB boosted its position in shares of Repligen by 11.8% during the second quarter. Handelsbanken Fonder AB now owns 22,070 shares of the biotechnology company’s stock worth $3,011,000 after acquiring an additional 2,332 shares during the last quarter. Everhart Financial Group Inc. purchased a new position in Repligen during the second quarter valued at $303,000. Assenagon Asset Management S.A. purchased a new position in Repligen during the second quarter valued at $9,687,000. Finally, Balefire LLC bought a new stake in Repligen in the 2nd quarter valued at $275,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.